In a filing, Apellis Pharmaceuticals Inc revealed its Chief Executive Officer Francois Cedric unloaded Company’s shares for reported $0.4 million on Jul 17 ’25. In the deal valued at $20.21 per share,19,725 shares were sold. As a result of this transaction, Francois Cedric now holds 331,605 shares worth roughly $6.39 million.
Then, Watson David O. sold 5,000 shares, generating $97,750 in total proceeds. Upon selling the shares at $19.55, the General Counsel now owns 128,730 shares.
Before that, Francois Cedric bought 19,725 shares. Apellis Pharmaceuticals Inc shares valued at $397,552 were divested by the Officer at a price of $20.15 per share.
Raymond James downgraded its Apellis Pharmaceuticals Inc [APLS] rating to an Outperform from a a Strong buy in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering APLS with “an Overweight” recommendation on April 29, 2025. Goldman revised its rating on December 17, 2024. It rated APLS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of APLS
On Monday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -0.98% to $19.28. Over the last five days, the stock has lost -3.16%. Apellis Pharmaceuticals Inc shares have fallen nearly -51.18% since the year began. Nevertheless, the stocks have fallen -39.58% over the past one year.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2025-06-13, dropping by -2.11 million shares to a total of 25.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 27.25 million shares. There was a decline of -8.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 21, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $31 price target.
